Kerala Mpox: Global Strain Found, India Surveillance Lags

The recent identification of Clade Ib mpox in Kerala, India, isn’t a signal of a looming outbreak – at least, not yet. It’s a stark warning about the fragility of India’s public health infrastructure and its preparedness for emerging infectious diseases. While the current cluster is small and contained, the underlying vulnerabilities exposed by this case highlight a systemic lack of investment in genomic surveillance, vaccine readiness, and travel-related disease monitoring, weaknesses that could prove catastrophic with the arrival of a more virulent pathogen.

The Deep Dive: A Pattern of Reactive, Not Proactive, Public Health

The re-emergence of mpox, even in limited clusters, underscores a recurring theme in global public health: the tendency to react to outbreaks rather than proactively building robust surveillance and response systems. Mpox, historically confined to Central and West Africa, expanded globally after 2022, demonstrating its capacity for international spread. The current situation in Kerala isn’t unique; it mirrors patterns seen in other countries where initial cases were imported and then experienced limited local transmission. The critical difference lies in the ability to detect that transmission quickly and accurately.

India’s reliance on PCR testing without routine genomic sequencing is a significant handicap. Without understanding the specific strain circulating, authorities are essentially flying blind, unable to determine the origin of infections or track potential mutations. This is particularly concerning given the high volume of international travel to and from India, especially through states like Kerala with large expatriate populations. The fact that most patients developed symptoms after returning home suggests a significant number of undetected importations are occurring. The infrastructure built during the COVID-19 pandemic for genomic sequencing, while promising, was not sustained, representing a lost opportunity to bolster long-term pathogen monitoring capabilities.

The Forward Look: A Looming Threat Beyond Mpox

The Kerala cluster is a microcosm of a larger, more dangerous problem. The absence of systematic screening at airports and ports, coupled with slow turnaround times for genomic sequencing, creates a perfect storm for undetected introductions of novel pathogens. The Serum Institute of India’s agreement to manufacture the mpox vaccine is a positive step, but it’s meaningless without a clear national vaccination strategy. The questions remain: who gets vaccinated, when, and under what circumstances? Will India adopt a ring vaccination strategy, focusing on close contacts of confirmed cases? Currently, there’s no answer.

The WHO’s continued monitoring of Clade Ib and its warning that mpox is now a permanent global public health concern should serve as a wake-up call. However, the real threat isn’t necessarily mpox itself, but the lessons it reveals about India’s preparedness for the next emerging infectious disease. As public health expert S S Lal aptly points out, the gaps exposed by this episode will become “far more dangerous” when a more transmissible and virulent pathogen arrives.

The immediate need is for a dedicated national genomic surveillance program, not just for mpox but for all emerging zoonotic diseases. This requires sustained funding, investment in laboratory capacity, and a commitment to rapid data sharing. Furthermore, a comprehensive national vaccination policy, including a clear framework for vaccine deployment, is essential. Finally, strengthening travel-related disease monitoring, including potential screening measures at points of entry, is crucial to prevent future importations. The time to build these systems is now, before the next outbreak forces a reactive – and potentially devastating – response. As Dr. Sylvia Karpagam emphasizes, “The system has to be built before the next outbreak, not after it.”